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SUMMARY

Alterations in distal regulatory elements that control gene expression underlie many diseases, including cancer. Epigenomic analyses of normal and
diseased cells have produced correlative predictions
for connections between dysregulated enhancers
and target genes involved in pathogenesis. However,
with few exceptions, these predicted cis-regulatory
circuits remain untested. Here, we dissect cis-regulatory circuits that lead to overexpression of NEK6,
a mitosis-associated kinase, in human B cell lymphoma. We find that only a minor subset of predicted
enhancers is required for NEK6 expression. Indeed,
an annotated super-enhancer is dispensable for
NEK6 overexpression and for maintaining the architecture of a B cell-specific regulatory hub. A CTCF
cluster serves as a chromatin and architectural
boundary to block communication of the NEK6 regulatory hub with neighboring genes. Our findings
emphasize that validation of predicted cis-regulatory
circuits and super-enhancers is needed to prioritize transcriptional control elements as therapeutic
targets.

INTRODUCTION
Cell identity and function rely on stringently controlled programs
of gene expression, perturbations of which underlie diseases,
including autoimmunity and cancer. Genome-wide association
studies have revealed that most pathogenic changes in gene
expression are linked to variants in regulatory elements rather
than coding sequences (Maurano et al., 2012). A dissection of
cis-regulatory circuits controlling transcriptomes in normal and
diseased cells remains an important objective. Most cis-regulatory circuits are composed of gene-proximal promoters and
distal enhancers, which serve as conduits for transcription factors (TFs) and communicate with each other via physical contact,

forming a series of loops in nuclear chromatin (Bulger and Groudine, 2011).
Conventional enhancers (CEs), both active and poised, can be
identified in the genome as nucleosome-free regions. The activity level of each conventional enhancer is revealed by the density
of certain histone modifications, prototypically histone H3 acetylated at lysine 27 (H3K27ac) (Bulger and Groudine, 2011).
Recent epigenome analyses have revealed a new class of
regulatory regions, coined super-enhancers (SEs) (Whyte
et al., 2013), which are characterized by broad stretches of
H3K27ac. Most SEs are dense clusters of highly active CEs,
which bind lineage-restricted TFs. Indeed, SEs normally colocalize with a limited set of genes that are most essential for
cell identity and function. The acquisition or amplification of
SEs near oncogenes contributes to several classes of cancer
(Hnisz et al., 2013; Mansour et al., 2014). SEs are also enriched
for disease-associated sequence variants, some of which presumably disrupt TF binding sites to alter super-enhancer function and expression of its associated gene(s) (Hnisz et al.,
2013; Koues et al., 2016). However, contributions of SEs to
gene expression programs have been mostly assumed from
correlative chromatin profiling rather than by direct testing
(Proudhon et al., 2016). Furthermore, it remains controversial
whether SEs represent a new paradigm in transcriptional regulation or merely clusters of CEs that additively promote transcription (Dukler et al., 2016; Hay et al., 2016).
In addition to cis-regulatory elements, gene expression programs are significantly influenced by chromosome architecture,
which facilitates or impairs promoter-enhancer contacts. The
architecture of mammalian genomes is compartmentalized into
topologically associated domains (TADs), which are highly
conserved among cell types and species (Dixon et al., 2012).
Loci within each TAD interact with one another but are largely
cordoned off from neighboring TADs. Each of these architectural
building blocks is subdivided into structures called sub-TADs or
contact domains, which are composed of loops between CTCF
binding elements (structural loops) or between promoters and
enhancers (regulatory loops). At a biochemical level, structural
loops form via dimeric interactions between CTCF proteins
bound in a convergent orientation at two distinct sites and are
stabilized by association with the ring-like cohesin complex
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(Ghirlando and Felsenfeld, 2016; Rao et al., 2014). The bases of
many structural loops serve as boundary elements that partition
active and inactive chromatin domains within TADs and limit
inappropriate interactions of regulatory elements with neighboring genes (Hnisz et al., 2016a; Ong and Corces, 2014). In
keeping with their structural determinants, contact domains,
unlike TADs, may vary significantly between cell types, developmental stages, or activation status (Dixon et al., 2016). Indeed,
key questions remain about how intra-TAD architectures form
and change during cellular differentiation and transformation.
Answers to these fundamental questions will impact our understanding of not only basic gene regulatory mechanisms but
also the etiology of many diseases. A substantial subset of disease-associated SNPs and genomic alterations disrupts CTCF
sites, breaking architectural borders and allowing inappropriate
communication between enhancers and alternative genes
(Lupiáñez et al., 2015; Hnisz et al., 2016b).
Similarly, a deeper understanding of the regulatory determinants that underlie oncogenic gene expression programs remains a basic mission of cancer research (Sur and Taipale,
2016). Pathogenic expression programs have been characterized for many cancers, including various types of B cell lymphoma (BCL) (Jiang et al., 2016; Morin et al., 2010). A common
class of BCL, termed follicular lymphoma (FL), is incurable.
Most FLs exhibit an indolent clinical course but often transform
to a more aggressive cancer, termed diffuse large BCL (DLBCL)
(Lenz and Staudt, 2010). Recently, we showed that pathogenic
gene expression programs in FL are coordinated by a common
set of TFs that, in turn, augment or attenuate activities of their
target enhancers when compared with normal B cell counterparts, termed centrocytes (CCs) (Koues et al., 2015). Integrative
transcriptome and epigenome analyses revealed a blueprint of
pathogenic cis-regulatory circuits associated with FL, which predicted connections between distal enhancers and promoters of
dysregulated genes. Similar correlation-based circuitries governing gene expression have been constructed for many normal
and transformed cell types (Thurman et al., 2012), revealing a
new collection of potential targets for epigenetic therapeutics.
However, the validity of predicted circuits remains largely
untested at the functional level. This gap is particularly important
given that a majority of predicted cis-regulatory circuits consist
of multiple enhancers connected to a single gene or, conversely,
multiple genes connected to a single enhancer (Thurman et al.,
2012).
Here, we functionally dissect a predicted cis-regulatory circuit
for the mitosis-associated kinase NEK6, which is commonly
overexpressed in BCL (Mareschal et al., 2015). We find that
only a subset of CEs, predicted by correlative algorithms to
regulate NEK6 in BCL, is required to maintain its elevated
expression. Strikingly, a B cell-specific super-enhancer is completely dispensable for NEK6 expression and maintenance of a
regulatory hub that co-localizes its promoter with many distal
CEs. A cluster of CTCF sites at one border of the NEK6 contact
domain serves as a chromatin and architectural boundary to
minimize the functional impact of its regulatory hub with neighboring genes. Our study not only provides insights into how
NEK6 expression is regulated in normal and pathogenic B cells
but also emphasizes the need to rigorously test predictions,

based solely on chromatin landscapes, regarding cis-regulatory
circuits and super-enhancer function.
RESULTS
The NEK6 cis-Regulatory Circuit Distinguishes FL
Subsets
Very few correlation-based predictions for cis-regulatory circuits
in normal or transformed cells have been validated functionally
by targeted engineering of control elements within their native
chromosomal context (Sur and Taipale, 2016). To rigorously
test a manageable set of predictions, we prioritized pathogenic
cis-regulatory circuits associated with CC transformation into
FL (Koues et al., 2015). Prioritization of differentially expressed
genes and their corresponding regulomes was tiered for recurrence of pathogenic enhancers in FL samples, altered levels of
gene expression, relevant TF binding, and gene function (Figure S1A; Supplemental Experimental Procedures; Table S1).
The scheme yielded seven regulatory clusters and accompanying genes, which we considered to be of high priority for functional dissection (Table S2). Each of the seven regions consists
of multiple enhancers and potential target genes, which renders
comprehensive analysis of all prioritized circuits unwieldy. From
the seven, we selected a region spanning NEK6 and several
neighboring genes for in-depth functional studies, based on multiple criteria. We first tested enhancer activities using luciferase
reporters for a series of regulatory elements from the seven surviving regions, each of which displays augmented H3K27ac in FL
compared with CCs. A regulatory element in the NEK6 region
(CE1) displays the most robust enhancer activity in both an
EBV-transformed B cell line (GM12878) and a human BCL line
(Farage; Figure S1B). Moreover, NEK6, a central gene in the
identified circuit, encodes a serine/threonine kinase that mediates mitotic progression, is overexpressed in many cancers,
and is essential for sustained growth of tumors derived from
numerous tissues (Fry et al., 2012).
With regard to B cell oncogenesis, NEK6 expression distinguishes the two known subtypes of DLBCL, exhibiting elevated
expression in the germinal center (GC) compared with the activated B cell (ABC) subtype (Mareschal et al., 2015). Epigenome
analyses revealed that FL also segregates into two analogous
classes (Koues et al., 2015), subtype 1 (GC-like) and subtype 2
(ABC-like). Strikingly, NEK6 expression is significantly elevated
in subtype 1 FL, further highlighting its similarity to GC-DLBCL
(Figure 1A). One final criterion in selecting the NEK6 region for
further study is its rich regulatory landscape, which seemingly
consists of multiple enhancers augmented in BCL and a series
of potential architectural elements (see below). Thus, we suspected that analysis of NEK6 cis-regulatory circuits would provide insights into enhancer and architectural elements important
for cell-type-, lymphoma-, or FL-subtype-specific expression of
this mitosis-associated kinase.
The NEK6 Regulatory Landscape
To identify the collection of distal architectural and regulatory
elements that contribute to elevated NEK6 expression in BCL,
we leveraged data from public databases (ENCODE Project
Consortium, 2012; Koues et al., 2015). Nucleosome-depleted

Cell Reports 18, 2918–2931, March 21, 2017 2919

A

B

C

D

E

(legend on next page)

2920 Cell Reports 18, 2918–2931, March 21, 2017

regions demarcate more than a dozen active or poised elements
spread over a 500-kb region encompassing NEK6 and its neighboring genes (Figure 1B; formaldehyde-assisted isolation of regulatory elements sequencing [FAIRE-seq]/DNase I hypersensitive site sequencing [DNase-seq]). Several of these regions
are bound by architectural factors, CTCF and RAD21, in
GM12878, suggesting they may serve as structural or boundary
elements (CTCF sites, CS1–7). NEK6 has two annotated transcription start sites (TSSs), which are both active in human B
cells and GM12878 (Figure S1C). H3K27ac peaks coincide
with 14 nucleosome-depleted regions in FL samples, indicating
positions of active conventional enhancers (CE1–14). Importantly, many of these enhancers exhibit a higher density of
H3K27ac in FL compared with normal CC counterparts, suggesting they are hyperactive in transformed B cells. A subset
of active enhancers (CE3–9) is clustered in a region 63 to
40 kb upstream of NEK6, which is designated as a superenhancer (SE1) in both FL and CC samples using the rank
ordering of super-enhancers (ROSE) algorithm (Lovén et al.,
2013; Whyte et al., 2013) to analyze H3K27ac chromatin immunoprecipitation sequencing (ChIP-seq) data (Figure 1C). When
compared with other cell types, the activities of CE1, CE10,
and SE1 are primarily restricted to B cells (Figure S1D). Another
conventional enhancer region, CE13–14, is also active in a subset of other cell types that express NEK6. These epigenome analyses suggest that CE1, CE10, SE1 and, perhaps, CE13–14 are
critical enhancers for driving high levels of NEK6 expression in
activated or transformed B cells.
Extensive genetic manipulations are required to dissect the
NEK6 regulome; however, this approach is currently infeasible
using primary human B cells. As such, we identified a tractable
cell model that mirrors the NEK6 chromatin landscape in primary FL. As shown in Figure 1B, the transformed human
B cell line GM12878 meets this criterion, while the human T
lymphocyte cell line Jurkat exhibits a chromatin landscape
largely devoid of active regulatory elements near NEK6, thus
providing a negative control. In addition to recapitulating
patterns of active enhancers in primary B and FL cells, the
CE3–9 region is classified as a super-enhancer in GM12878
(Figure 1C). NEK6 expression in GM12878 is comparable to
levels observed in tonsillar B cells, the majority of which are
activated, whereas NEK6 transcripts are nearly undetectable
in Jurkat (Figure 1D).

In addition to NEK6, two neighboring genes, LHX2 and
PSMB7, are predicted to connect with many of the B cellrestricted enhancers in FL using a gene circuitry algorithm
(Koues et al., 2015). LHX2 is a TF involved in the differentiation
of developing lymphoid and neural cell precursors and is a putative oncogene for pancreatic tumors (Zhou et al., 2014). PSMB7
is a proteasome subunit that was identified as a biomarker for
breast and colon cancers (Munkácsy et al., 2010). As shown in
Figure 1E, expression of these two genes, but not the more distal
DENND1A, are modestly elevated in FL and/or tonsillar B cells
compared with human CCs. All of these genes are expressed
at varying levels in GM12878 (Figure S1E). As such, functional
dissection of the NEK6 cis-regulatory circuit can be achieved
using GM12878, which recapitulates prominent features of the
FL regulome.
Spatial Convergence of NEK6 Distal Regulatory
Elements
Proper control of gene expression requires direct contact of
distal regulatory elements with their target promoters. Many
cell-type-specific contacts between enhancers and promoters
are confined within TADs and further restricted by boundary
elements to minimize inappropriate enhancer-promoter communication. To elucidate the NEK6 interactome within its
chromosomal neighborhood, we analyzed publicly available
genome-wide chromosome conformation capture (Hi-C) data
for a 2-Mb region in GM12878 (Figure 2A) (Rao et al., 2014).
Based on interactomes conserved among cell types, the TAD
containing NEK6 spans 1 Mb encompassing DENND1A,
LHX2, NEK6, and PSMB7. In GM12878, this region also contains
several sub-TADs, one of which includes NEK6, spanning from
the DENND1A promoter to PSMB7 (500 kb). Within the subTAD, there is a robust contact domain spanning from the cluster
of upstream CTCF sites (CS2–4) to the downstream NEK6 promoters (TSS1–2). More focal contacts are observed between
both NEK6 promoters and pockets of upstream regulatory
elements, especially with CE1 and SE1. Hi-C data revealed
associations of the NEK6 locus with PSMB7 and, to a lesser
extent, with LHX2, suggesting a potential mechanism for their
elevated expression in FL. Finally, NEK6 is flanked by two sets
of CTCF sites pointing in convergent orientations, a trio located
130 kb upstream of TSS1 (CS2–4) and a pair located in a
NEK6 intron (CS5) and near the PSMB7 promoter (CS6). The

Figure 1. The NEK6 Regulatory Landscape in Normal and Transformed Cells
(A) Expression levels of NEK6 in primary human cells. Each dot represents normalized microarray signals for a purified B cell sample from independent healthy
volunteers or FL biopsies (CC, tonsillar centrocytes; TsB, unfractionated tonsillar B cells). Statistical tests were performed for subtype 1 or 2 FL versus other cell
types. Only significant differences are shown for clarity (unpaired t test with Welch’s correction): ***p < 0.005 and ****p < 0.001.
(B) Scheme depicting genes and regulatory elements in the NEK6 neighborhood. Red circles represent CEs that are FAIRE and H3K27ac positive in at least two
FL samples from previously published data (Koues et al., 2015). Orange arrowheads depict CSs, as well as their orientations, as identified by chromatin profiling.
UCSC Genome Browser views are shown for FAIRE-seq and H3K27ac ChIP-seq data from FL and CC samples (Koues et al., 2015), as well as DNase-seq, H3K27ac,
CTCF, and RAD21 ChIP-seq data in GM12878 (GM) and Jurkat cell lines (ENCODE). All sequencing data are presented as reads per million mapped reads.
(C) Rank order of increasing H3K27ac enrichment at enhancers in the indicated cell types. SEs were called using ROSE, with the NEK6-associated super
enhancer highlighted.
(D) NEK6 transcripts in the indicated cell types measured by qRT-PCR. Results represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired t test with Welch’s correction (*p < 0.05, ***p < 0.005, and ****p < 0.001).
(E) Expression levels of NEK6 neighboring genes in primary B cell samples, as measured by microarray. Each dot represents an independent sample. Statistical
significance was determined using an unpaired t test with Welch’s correction (*p < 0.05, ***p < 0.005; n.s., not significant).
See also Figure S1.
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Figure 2. The NEK6 Regulatory Hub
(A) Hi-C data for the NEK6 region in GM12878, as visualized in Juicebox (Rao et al., 2014). The intensity of each pixel represents relative normalized numbers of
contact between corresponding regions, for which red and blue represent enriched or depleted interaction frequencies, respectively. Knight and Ruiz
normalization (balanced) is applied to remove locus-specific biases. The observed over expected (O/E) signal is displayed to account for a higher number of
interactions with closer regions due to one-dimensional proximity (Rao et al., 2014). Several chromatin structures and contact points are highlighted with black
boxes. In the left panel, genes within the NEK6-TAD are colored red and remaining genes are colored blue.
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convergent orientation favors loop formation between CTCF regions (Ghirlando and Felsenfeld, 2016; Rao et al., 2014), perhaps
spatially sequestering the NEK6 regulome.
To determine whether this regulatory architecture is cell-type
specific, we performed chromosome conformation capture
(3C) assays in GM12878 (NEK6+) and Jurkat (NEK6), which
directly probes interactions between a given viewpoint and
selected regions of the NEK6 chromosomal neighborhood. As
shown in Figure 2B, a viewpoint spanning TSS1 interacts with
upstream regulatory regions and with TSS2 at significantly
higher frequencies in GM12878 compared with Jurkat. Peak
TSS1 associations are with the CTCF cluster (CS2–4), CE1,
CE2, and sites within SE1. To further validate the NEK6 interactome, we assayed a number of complementary viewpoints.
Interactions with the distal CE1 element are significantly higher
throughout the NEK6 sub-TAD in GM12878 compared with
Jurkat. The enhanced CE1-PSMB7 contacts were confirmed
using a PSMB7 promoter viewpoint (Figure S2A). Coupled with
3C assays using viewpoints in SE1 (Figures S2B and S2C),
TSS2 (Figure S2D), and the CTCF cluster (Figure S2E), we
conclude that the upstream region of NEK6 folds into a celltype-specific regulatory conformation, forming a hub for enhancers, promoters, and CTCF sites, which likely drives higher
levels of NEK6 expression in activated B cells.
Conventional Enhancers Augment NEK6 Expression in
Transformed B Cells
Our ultimate goal is to test predictions for key components of the
cis-regulatory circuit associated with elevated NEK6 expression
in transformed B cells. Chromatin profiling and interactome analyses revealed over a dozen enhancer elements that could
potentially augment NEK6 expression in FL. To prioritize functional analyses, we first measured enhancer activities for each
candidate regulatory element in GM12878 and Jurkat (Figures
3A and S3A). In addition to the robust, GM12878-specific
enhancer activity of CE1, four other elements augment luciferase
expression from SV40-promoter-driven reporters. These include
two regions in SE1 (CE5 and CE9), the CE10 region upstream of
TSS1 and the CE13 region upstream of TSS2. Despite its significant levels of interaction with NEK6 promoters (Figure 2B), CE2
lacks enhancer activity in GM12878, which is consistent with
minimal deposition of H3K27ac over this region (Figure 1B).
The activity status of CEs was bolstered by ChIP-seq data
from GM12878 (ENCODE Project Consortium, 2012), which reveals significant peaks for EP300 and TFs important in B cell
biology, including EBF1, OCT2, PU.1, PAX5, RELA, and TCF3
(Figure S3B). In contrast, CE2 lacks significant binding by any
of these factors. These functional data led us to first focus on
the role of three CEs located outside of SE1, which had the
most robust activities in GM12878 (CE1, CE10, and CE13).
To test the contributions of selected CEs to NEK6 expression,
we individually deleted each enhancer from its endogenous site
in GM12878 using CRISPR/Cas9 technology (Table S3). Deletion

of CE13, which is proximal to TSS2, produces a modest but significant decrease in NEK6 expression when compared with
subclones retaining the enhancer on both alleles (Figure 3B).
Ablation of CE10 has no significant impact on NEK6 expression,
despite its enhancer activity in luciferase assays. Importantly,
NEK6 expression is attenuated substantially in subclones lacking the most distal enhancer, CE1, located 120 kb from TSS1.
Consistently, NEK6 protein levels are dramatically reduced in
CE1/ subclones as measured by western blotting (Figure S3C).
The effects of each enhancer deletion are indistinguishable for
transcripts derived from either TSS1 or TSS2 (Figure S3D). Moreover, neither the CE1 nor the CE13 enhancer deletion impacts
expression of neighboring LHX2 and PSMB7 genes (Figure S3E).
These data suggest that CE1 and CE13 both contribute to
augmented NEK6 expression in transformed B cells. Indeed,
compound deletion of both elements further diminishes NEK6
mRNA and protein expression (Figures 3C and S3C). We
conclude that two conventional enhancers, positioned outside
of the large super-enhancer, additively potentiate NEK6 expression in GM12878.
To probe the effects of enhancer deletions on NEK6 chromatin
and interaction landscapes, we analyzed subclones using ChIP
and 3C, respectively. Deletion of CE13 reduces H3K27ac to
near-background levels at an adjacent region, verifying removal
of the core enhancer (Figure 3D). H3K27ac levels in CE13/ mutants are unaffected at all other NEK6 enhancers tested. In sharp
contrast, deletion of CE1 leads to significant reductions in
H3K27ac not only at an adjacent region but also at many locations within SE1 and other enhancers that associate with CE1.
These data suggest that CE1 is a dominant element in sculpting
the active epigenetic landscape near NEK6, perhaps through
spatial interactions that form its regulatory hub. In this regard,
the TSS1 interactome is unaffected by deletion of either CE13
or CE1 (Figure 3E). Likewise, CE1 deletion does not alter longrange interactions between this region and downstream regulatory elements, including the TSSs (Figure S3F). However,
deletion of CE13 slightly boosts associations of CE1 with downstream enhancers, as well as NEK6 TSSs (Figure S3G). This
finding suggests that CE13 may partially compete with CE1 for
association with TSSs and other elements of the regulatory
hub. When CE13 is deleted, there may be a compensatory increase in CE1 interactions.
To further test whether the dominant CE1 element is dispensable for maintaining the NEK6 interactome, we performed circular chromosome conformation capture sequencing (4C-seq) on
GM12878, as well as three independent CE1/ and two wildtype subclones. Genome-wide interactome data probed from
CE1 and TSS1 viewpoints show that CE1 deletion subclones
have no significant differences for interactions with regions between CS2 and downstream of TSS2 (Figures 3F and S3H), validating our 3C findings. These data indicate that maintenance of
the NEK6 regulatory hub, which includes the distal CTCF cluster,
CE1, SE1, CE13, and TSSs, is independent of the dominant

(B) Interaction frequencies, as measured by 3C-qPCR, for NEK6 TSS1 (top) and CE1 (bottom) viewpoints in GM12878 (NEK6 expressed) and Jurkat (NEK6 silent).
Results represent the mean ± SEM of three independent experiments. Statistical significance was determined using an unpaired t test with Welch’s correction
(*p < 0.05).
See also Figure S2.
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conventional enhancer, CE1. However, this element contributes
significantly to the maintenance of active chromatin marks at
other CEs in the regulatory hub, boosting NEK6 expression in
GM12878.
The NEK6 Super-Enhancer Is a Bystander
Super-enhancers are thought to be dominant regulatory elements for genes controlling cell identity, major cellular functions,
and, in some cases, oncogenesis (Hnisz et al., 2013). Our
chromatin analysis identified SE1, a 23-kb region located between CE1 and the TSSs, as a B cell-specific NEK6 superenhancer. Although two conventional enhancers (CE1 and
CE13) contribute to NEK6 expression, a substantial level of transcripts remains following their deletion, further implicating SE1
as an important regulatory element. To test this directly, we
deleted the entire SE1 region from both alleles of GM12878 using
CRISPR/Cas9. Surprisingly, multiple independent clones lacking
SE1 consistently express NEK6 mRNA at modestly higher levels
when compared with subclones retaining an SE1+/+ configuration (Figure 4A). Removal of SE1 also enhances or has minimal
impact on NEK6 protein expression (Figure S3C). ChIP analysis
revealed a depletion of H3K27ac neighboring the deleted SE1,
confirming removal of the super-enhancer (Figure 4B). However,
SE1 deletion does not impact H3K27ac levels at other tested
CEs. Moreover, compound deletion of SE1 on one allele of
CE1/ clones has no significant impact on NEK6 expression
(Figure 4A).
One potential explanation for enhanced NEK6 expression
following SE1 removal is that CE1 resides 23 kb closer to its
promoters. However, this would imply that SE1 itself does not
contribute fundamentally to NEK6 expression. To explore the
impact of SE1 on the NEK6 regulatory hub, we performed
3C. As shown in Figure 4C, SE1 deletion potentiates interactions between TSS1 and more distal elements (CE1 and
CE2). The SE1/ clones also show enhanced associations
between TSS1 and more proximal regulatory regions (CE10
and TSS2), whose linear distances are unaffected by SE1 deletion. These data suggest that SE1 has a modest inhibitory
impact on the frequency of enhancer associations in the
NEK6 regulatory hub, as well as overall expression of this
gene in GM12878.

An alternative explanation for the lack of SE1 regulatory function is that removal of critical enhancer elements drop NEK6
levels below a threshold required for GM12878 proliferation or
survival. To test this possibility, we depleted NEK6 using several
independent small hairpin RNAs (shRNAs). Reduced levels of
NEK6 protein (20%–30% normal; Figures S4A and S4B) have
no detectable impact on either proliferation or survival of
GM12878 (Figures S4C and S4D). The lack of a biological phenotype may also stem from expression of NEK7 in these cells, a
closely related kinase with significant functional overlap (Fry
et al., 2012). These data indicate that selective pressure from
reduced NEK6 levels cannot reasonably explain the lack of a significant expression phenotype in SE1-deficient cells.
Although SE1 is dispensable for NEK6 expression in
GM12878, it remains possible that this broad regulatory region
may target another gene in its chromosomal neighborhood.
Focused qRT-PCR analysis of SE1/ clones revealed no significant change in PSMB7 expression (Figure 4D). Similar to its
effect on NEK6, SE1 deletion modestly enhances levels of
LHX2 transcripts. To explore potential SE1 roles on a more
global level, we analyzed three independent GM12878 subclones with SE1+/+ or SE1/ genotypes using RNA sequencing
(RNA-seq). SE1 deletion does not significantly change steadystate expression of any gene located within 5 Mb (Figure 4E).
On the transcriptome level, six genes are significantly increased
or decreased in SE1/ clones compared with their wild-type
counterparts (Figure S4E). The six genes are located on five
different chromosomes; however, published promoter-capture
Hi-C data reveal no significant inter-chromosomal interactions
between any of the gene promoters and SE1 in GM12878
(Mifsud et al., 2015). We conclude that SE1, although clearly
assigned as a super-enhancer using current algorithms, has no
identifiable regulatory impact for maintaining expression of its
nearest neighbors or any gene in a large chromosomal swath
centered on NEK6.
A CTCF Cluster Establishes the NEK6 Contact Domain,
but Not the Regulatory Hub
Our functional data clearly demonstrate that two conventional
enhancers, CE1 and CE13, additively increase NEK6 expression
in transformed B cells. The more distal of these two elements,

Figure 3. CEs Potentiate NEK6 in Transformed B Cells
(A) Luciferase reporter assays for 14 putative CEs near NEK6. Enhancer activities were measured transiently in GM12878 or Jurkat cells and calculated relative to
an SV40 promoter-only reporter construct. Human IGH enhancer was included as a positive control. Results show the mean ± SEM of at least four independent
experiments in GM12878 and at least two in Jurkat.
(B and C) NEK6 transcripts, as measured by qRT-PCR, in GM12878-derived CRISPR deletion subclones generated from individual (B) or compound (C) enhancer
deletions and Jurkat cells as a negative control. Each dot represents the Jurkat cell line or a unique subclone of GM12878, reported as the average of two
independent RNA preparations, reverse transcription, and qPCR assays, the latter performed in triplicate. Statistical significance was determined using an
unpaired t test with Welch’s correction (*p < 0.05, **p < 0.01, and ***p < 0.005).
(D) H3K27ac ChIP assays in GM12878-derived subclones harboring deletions of CE13 (left) or CE1 (right). ChIP-DNA was analyzed by qPCR with primers in or
adjacent to indicated CEs. ChIP assays with a non-specific IgG antibody are shown as controls. For (D) and (E), each bar represents the mean ± SEM of
two subclones, each of which includes two independent experiments. Statistical significance was determined using an unpaired t test with Welch’s correction
(*p < 0.05).
(E) Interaction frequencies, as measured by 3C-qPCR, in deletion subclones of CE13 (left) and CE1 (right) for the NEK6 TSS1 viewpoint.
(F) UCSC Genome Browser views of interaction profiles, as measured by 4C-seq, for CE1 wild-type and deletion subclones using CE1 and NEK6-TSS1 as
anchors. For each viewpoint, the average counts per HindIII fragment normalized by DESeq2 are shown for three wild-type (red) and three CS2–4 deletion lines
(green). A plot for differential signal between deletion and wild-type samples (Del-WT) is displayed below. None of the differences are statistically significant
(DESeq2). The deleted CE1 region is shown as a yellow rectangle.
See also Figure S3.
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Figure 4. SE1 Is a Dispensable Element in the NEK6 Regulome
(A) NEK6 transcripts measured by qRT-PCR of SE1 deletion subclones. Each dot represents a unique subclone, which is reported as the average of two
independent experiments. See Figures 3B and 3C for details. For (A)–(D), statistical significance was determined using an unpaired t test with Welch’s correction
(*p < 0.05).
(B) H3K27ac ChIP assays in SE1 deletion subclones. See Figure 3D for details. For (B) and (C), each bar represents the mean ± SEM of two subclones, each of
which includes two independent experiments.
(C) Interaction frequencies, as measured by 3C-qPCR, in SE1 deletion subclones for NEK6 TSS1 (left) and CE1 (right) viewpoints.
(D) LHX2 and PSMB7 transcripts measured by qRT-PCR in SE1 deletion subclones. Each dot represents a unique subclone, which is reported as the average of
two independent experiments.
(E) Expression profile for all genes located within 5 Mb of SE1, as measured by RNA-seq, in SE1 wild-type and deletion subclones of GM12878. Average logCPM
indicates the average expression level of each gene among three wild-type and three deletion subclones, reported as log2 read counts per million mapped reads.
Log(SE1 Del/WT) represents the log2 fold-change of each gene between the average CPM of deletion versus wild-type subclones. Blue lines denote 2-fold
differences.
See also Figure S4.

CE1, requires long-range looping (>120 kb) to communicate with
NEK6 promoters. Architectural elements, largely consisting of
CTCF sites, are common mediators of long-range looping that
facilitate enhancer contact with gene promoters. Moreover,
some CTCF sites serve as boundary elements to compartmentalize chromatin domains and inhibit inappropriate communication between enhancers and other neighboring genes (Ghirlando
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and Felsenfeld, 2016). CE1 is flanked by a cluster of CTCF sites
positioned at one border of a robust contact domain containing
NEK6. All three sites in this cluster are oriented convergently with
a pair of downstream CTCF sites, located in a NEK6 intron (CS5)
and near the PSMB7 promoter (CS6). The convergent orientation
favors intermolecular CTCF interactions, which could form loops
to cordon off NEK6-associated enhancers from other genes in
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the TAD. To explore architectural logic in the NEK6 cis-regulatory
circuit, we deleted a region spanning all three sites in the upstream CTCF cluster (CS2–4). Minimal CTCF binding is detected
at sites flanking CS2–4 following its deletion when compared
with wild-type loci (Figure 5A), whereas CTCF ChIP signals are
unaffected at CS5 and CS6. NEK6 expression is reduced
20% in subclones harboring the CS2–4 deletion on both alleles
(Figure 5B). In contrast, LHX2 expression is enhanced 60% in
knockout subclones, while expression of the two other genes
in this TAD, DENND1A and PSMB7, remains unchanged.
These data suggest that CS2–4 serves as a boundary element
to prevent the spread of active chromatin from NEK6 to LHX2,
minimize long-range interactions between NEK6 enhancers
and LHX2, or both (Ghirlando and Felsenfeld, 2016; Ong and
Corces, 2014). To test the first possibility, we measured
H3K27ac densities at sites in the NEK6 contact domain and
adjacent LHX2 regions (Figure 5C). Consistent with a role for
CS2–4 as a chromatin boundary, its deletion permits H3K27ac
spreading upstream of CE1 into the LHX2 locus. CS2–4 deletion
had an opposite effect on H3K27ac densities within the NEK6
contact domain, which are significantly reduced, accompanied
by an increase in the H3K27me3 modification (Figure S5A).
Thus, perturbed patterns of chromatin modifications correlate
well with altered gene expression upon deletion of the 50 CTCF
cluster, supporting its functional assignment as a boundary
element.
To determine whether CS2–4 also serves as a spatial boundary, precluding communication between NEK6 enhancers and
other promoters, we performed 3C on subclones with wildtype and CS2–4/ genotypes. As expected, mutant subclones
generate no 3C signal for interactions between TSS1 and the
deleted CS3 region (Figure 5D). All other interactions between
TSS1 and NEK6 regulatory elements are unaffected by CS2–4
deletion. In contrast, TSS1 interactions with the LHX2 and
DENND1A promoters, located further upstream in the subTAD, are significantly increased in mutant subclones. A similar
enhancement of upstream interactions is observed for the CE1
element with LHX2, but not DENND1A, which correlates with
the differential impacts of CS2–4 deletion on expression levels.
Conversely, CE1 associations are decreased with downstream

regions, including CS5 and the PSMB7 promoter. The enhanced
interactions with LHX2 were confirmed using a complementary
viewpoint corresponding to its promoter (Figure 5E).
To support these findings, we performed 4C-seq on
GM12878, as well as independent CS2–4/ and wild-type subclones (Figures 5F, S5B, and S5C). Genome-wide interactome
data probed from TSS1 and CE1 viewpoints reveal that, in general, CS2–4/ subclones have more robust associations with
upstream regions in the sub-TAD, reaching to the DENND1A
promoter, as reflected in percent total normalized reads (Figure 5F) (Guo et al., 2015). In contrast, interactions within the
NEK6 contact domain itself are slightly attenuated following
CS2–4 deletion (diminished percent normalized reads in Figures
5F and S5B). In addition, 4C-seq data identify several interactions that differ significantly between CS2–4/ and control
clones. Deletion of the CTCF cluster significantly augments interactions between CE1 and several regions upstream (Figure 5F,
green asterisks), as well as with the LHX2 promoter, although
the latter does not attain statistical significance in 4C data.
Conversely, multiple interactions of CE1 with downstream regions in the NEK6 gene body and PSMB7 promoter region are
significantly diminished following CS2–4 removal (Figure 5F,
red asterisks), consistent with our 3C data (Figure 5D). Similarly,
upon CS2–4 deletion, TSS1 has significantly elevated associations with the DENND1A and LHX2 promoters (Figure 5F).
A potential explanation for the latter finding is that new contact
loops may be formed between NEK6-proximal CTCF sites
(e.g., CS5) and the properly oriented CTCF site upstream of
the deleted CS2–4 region. A CTCF site located between the
DENND1A promoter and LHX2, designated as CS0, has the
same orientation as those deleted from the CS2–4 cluster (Figure 5F). Indeed, 3C analyses indicate that the CS2–4 deletion enhances CS0–CS5 interactions, whereas CS0–CS6 crosslinking
remains unaffected (Figure 5G). The architectural remodeling
of CTCF interactions, which may place the NEK6 gene in closer
proximity to LHX2 and DENND1A, was confirmed using the complementary CS5 viewpoint (Figure 5G). Together, these data
indicate that CS2–4 contributes modestly to establishing the regulatory hub between NEK6 promoters and enhancers. Instead,
this CTCF cluster predominantly functions as a chromatin and

Figure 5. CS2–4 Serves as a Chromatin and Architectural Boundary for the NEK6 Regulatory Hub
(A) CTCF ChIP assays in CS2–4 deletion subclones. ChIP-DNA was analyzed by qPCR using primers within or adjacent to indicated CSs. Each bar represents the
mean ± SEM of two subclones, each of which includes two independent experiments. ChIP assays with a non-specific IgG antibody were performed as
specificity controls. For (A)–(E) and (G), statistical significance was determined using an unpaired t test with Welch’s correction (*p < 0.05 and **p < 0.01).
(B) Transcript abundance of genes in the NEK6-TAD, as measured by qRT-PCR, for CS2–4 deletion subclones. Each dot represents a unique subclone, which is
reported as an average of two independent experiments. See Figures 3B and 3C for details.
(C) H3K27ac ChIP assays in C2-4 deletion subclones. See Figure 3D for details. Each bar represents the mean ± SEM of two subclones, each of which includes
two independent experiments.
(D and E) Interaction frequencies, as measured by 3C-qPCR, in CS2–4 deletion subclones for CE1, NEK6 TSS1 (D), and the LHX2 promoter (E) viewpoints. Each
dot in (D) or bar in (E) represents the mean ± SEM of two subclones, each of which includes two independent experiments.
(F) UCSC Genome Browser views of interaction profiles, as measured by 4C-seq, for CS2–4 wild-type and deletion subclones using CE1 and NEK6-TSS1 as
anchors. For each viewpoint, the average reads per HindIII fragment normalized by DESeq2 are shown for three wild-type (red) and three CS2–4 deletion lines
(green). Reads located within the deleted CS2–4 region (yellow rectangle) are removed from all samples. Percentages of total normalized reads are displayed
above each sample for regions upstream and downstream of CS2–4 deletion, as marked by double-headed arrow lines. For each viewpoint, a plot for differential
signal between deletion and wild-type samples in natural log scale, ln (Del-WT), is displayed below. Statistical significance (generalized linear model adjusted by
Benjamini-Hochberg procedure; p < 0.05) is denoted by green or red asterisks for interactions that are increased or decreased in CS2–4 mutants, respectively.
(G) Interaction frequencies, as measured by 3C-qPCR, in CS2–4 deletion subclones for CS0 (left), CS5 (middle), and CS6 (right) viewpoints. Each bar represents
the mean ± SEM of two subclones, each of which includes two independent experiments.
See also Figure S5.
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architectural boundary, minimizing the impact of the NEK6 regulatory hub on neighboring genes in its TAD.
DISCUSSION
Developmental and cell-type-specific regulation of genes is
orchestrated by changes in TF expression, enhancer activation,
and alterations in chromatin landscapes, including architecture.
Deciphering the contributions of each process to gene regulation
is especially important given that a vast majority of diseaseassociated changes in the genome affect expression levels
rather than coding potentials (Maurano et al., 2012). A prerequisite for understanding cis-regulatory circuits that govern normal
or pathogenic gene expression is the profiling of enhancers and
their contacts in distinct cell types. This milestone has largely
been achieved in several hematologic malignancies and normal
cellular counterparts (Chapuy et al., 2013; Koues et al., 2015).
Based on chromatin and architectural profiles, pattern-based
algorithms have been used to predict key regulatory connections
between enhancers and their target genes. However, there is a
critical need to test predicted circuits using reductionist, genetic
approaches.
In this study, we dissected cis-regulatory circuits within a
chromosomal neighborhood spanning at least three genes overexpressed in human BCL. Importantly, many predictions from
pattern-based algorithms for NEK6 were not substantiated
when tested directly. The predicted circuitry for pathogenic
NEK6 expression involved at least a dozen enhancers with
augmented H3K27ac loads in FL versus normal B cells. All of
the CEs, including those comprising a super-enhancer, directly
contact the NEK6 promoter in transformed B cells, further
strengthening their predicted contributions to its elevated
expression in BCL. Instead, we find that the NEK6 regulome is
dominated by two conventional enhancers: one located near
the TSSs (CE13) and a second, more powerful enhancer (CE1)
located 100 kb upstream. Although some of the predicted
enhancers for NEK6 bind an overlapping set of factors, CE1 exhibits higher loads of TF binding than other enhancers (Figure S3B), potentially explaining its dominant regulatory function.
CE13 has lower levels of bound TFs and enhancer activity in
luciferase assays, yet its proximity to TSSs may elevate its role
in NEK6 regulation. The remaining CEs and, surprisingly, the
super-enhancer, are all dispensable for NEK6 expression in
transformed B cells, despite correlative changes in epigenetic
and architectural landscapes. Thus, our study underscores the
pressing need to hone predicted circuitry through rigorous
testing. Although tedious, the emergence of high-throughput
methods for genetic dissection of TFs, enhancers, and chromosome architecture will speed achievement of this goal.
We suspect several potential reasons for disconnects between predictive algorithms and direct validation of cis-regulatory circuits. First, as shown here for NEK6, a dominant enhancer
can affect the chromatin profile of other regulatory elements in its
interactome. Deletion of CE1 attenuated H3K27ac loads on
other CEs spread throughout the NEK6 region. Thus, increased
CE1 activity in BCL likely augments H3K27ac on other elements
in the regulatory hub, even if they do not contribute substantially
to enhanced gene expression. Second, we cannot rule out that

some CEs function as ‘‘backup’’ elements to partially sustain
NEK6 expression if CE1 activity is destroyed. This may be true
for CE13, which contributes modestly to NEK6 expression in
the absence of CE1. However, SE1 does not appear to have
such a backup role, since deletion of the entire region, or its composite CEs (data not shown), has no significant effect on NEK6
expression, whether CE1 is present or not.
The most surprising and significant finding from our study is
that a clearly established super-enhancer has no discernable
impact on the expression of NEK6 or any other gene on its chromosome. This finding is especially notable given the building
dogma that SEs are a collection of key elements controlling
high-level expression of genes critical for cell identity and function, as well as oncogenesis (Lovén et al., 2013). This finding
not only underscores the need for functional evaluation of SEs
in many cell types but also brings to light a third potential explanation for discrepancies between predicted and validated cisregulatory circuits. Although the super-enhancer and a subset
of other CEs are dispensable for NEK6 expression, these elements may be required earlier in B cell development or transformation to initially activate or augment transcription of this kinase
gene. After these key activation events, SE1 or other CEs may
become dispensable, with CE1 primarily maintaining elevated
levels of NEK6 expression. These issues are currently intractable
in primary human B cells but may be approached in future
studies by deletion of analogous regulatory regions for mouse
NEK6. Notwithstanding, our findings indicate that at least a subset of SEs associated with oncogenesis would not be priority targets for current epigenetic-based therapeutic strategies to
squelch expression of associated genes (Lovén et al., 2013).
A second surprise to emerge from our studies concerned determinants for regulatory architecture of the NEK6 chromosomal
neighborhood. We found that most enhancers in this region
converge spatially to form a regulatory hub with NEK6 promoters
and flanking CTCF clusters. Although CE1 is the dominant NEK6
enhancer, its deletion does not significantly affect maintenance
of the regulatory hub. Likewise, deletion of CS2–4 has only a
modest impact on spatial interactions within this hub. These
findings suggest several intriguing possibilities for architectural
determinants of regulatory hubs, which await future dissection,
including (1) direct CE1-promoter interactions are redundant,
structurally, with CS2–4 looping to downstream CTCF sites;
(2) another element, excluding SE1 and CE1, is the key determinant for initiating regulatory hub formation; or (3) once the NEK6
sub-TAD is decorated with active histone modifications, homotypic chromatin interactions drive close association of the
promoter with regional enhancers (Lieberman-Aiden et al.,
2009). Nevertheless, our study identifies important dual roles
for CS2–4 as a chromatin and architectural boundary, impairing
the spread of active chromatin and enhancer interactions upstream of NEK6 into LHX2. Thus, many CTCF sites or clusters
predicted to be important for formation of architectural loops
may be more critical in establishing or maintaining borders of
regulatory domains.
Our findings will also inform future studies to determine how
NEK6 contributes to B lymphomagenesis. Despite consistent
overexpression of the mitosis-associated kinase in BCL, NEK6
depletion had no detectable impact on viability or proliferation
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of transformed human B cells, including complete NEK6
knockout in two BCL lines (data not shown). In contrast, NEK6
knockdown in other cancer models significantly attenuated cell
growth (Fry et al., 2012). We suspect that, in BCL, partial functional overlap with the closely related kinase NEK7 may explain
the lack of cellular phenotype. Indeed, NEK7 is overexpressed
in primary cells derived from BCL biopsy specimens compared
with their normal counterparts (Koues et al., 2015). Human
NEK6 and NEK7 loci appear to be partial duplicates of one
another, since both are flanked upstream by additional LHX
and DENND genes. However, unlike NEK6, the NEK7 locus is
devoid of chromatin hallmarks for active distal enhancers in B
lymphocytes, FL, or other cell types (ENCODE Project Consortium, 2012; Koues et al., 2015). These correlative data suggest that NEK family kinases are essential components of the
program for lymphomagenesis, requiring transformed B cells
to augment NEK6 as a complement, or a backup, to NEK7 overexpression, or vice versa. Thus, our dissection of the NEK6
regulome will be an important starting point to test such requirements in the GC program and oncogenic conversion to BCL.

by limiting dilution, and screened for deletions using multiple independent
primer pairs outside and inside of the gRNA target sites. gRNA sequences
are shown in Table S3. Most gRNAs were cloned into the Addgene vector
41824, while gRNAs for CE13 were cloned into pKLV-U6gRNA(BbsI)PGKpuro2ABFP (Addgene 50946). PCR primers for screening deletions are
provided in Table S3. PCR products spanning deletion sites were purified
and Sanger sequenced (Table S3). All molecular analyses were performed
on sibling subclones corresponding to parental and mutant genotypes in the
same experiment to avoid complications that might arise from drifts in bulk
GM12878 cultures and experimental variations.
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